Potential options for the treatment of "NAFLD", efficacy and safety results published in Ezemab 2022EASD

Translator: Dong Bingzi Department of Endocrinology, Affiliated Hospital of Qingdao University

Introduction: On September 19-23, 2022, the international endocrine field conference "2022 European Association for Diabetes Research Annual Meeting" was held
in Stockholm, Sweden in the form of "online + offline".

At the meeting, some scholars shared the results
of the study "Ezemab combined with statins in the treatment of non-alcoholic fatty liver disease: a randomized controlled trial ESSENTIAL study".

Research explores: the effect of ezemab on the improvement of fat content in the liver

Ezemab is an inhibitor of Niemann-PickC1-like1 (NPC1L1) and has a good lipid-lowering effect, but the therapeutic effect of ezemab on fatty liver is unknown
.

The main objective of the study was to evaluate the efficacy
of ezemab plus rosuvastatin in reducing liver fat in patients with non-alcoholic fatty liver disease (NAFLD) compared with rosuvastatin monotherapy.

The study was a randomized, controlled, open-label trial in which 70 patients with ultrasound confirmed NAFLD were treated with e-effebular 10 mg + rosuvastatin 5 mg or rosuvastatin 5 mg monotherapy for 24 weeks
.

Intrahepatic fat content is determined by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF), which is used to measure changes in
liver fibrosis.

Results: Eba meb combined with rosuvastatin treatment significantly reduced liver fat

After 24 weeks of observation, the results of the analysis are as follows:

➤ Ibremeb combined with rosuvastatin monotherapy significantly reduced liver fat compared with rosuvastatin monotherapy (mean difference: 3.
2%; P=0.
020）
。
MRI-PDFF was significantly reduced from baseline to trial endpoint in the combination and monotherapy groups (18.
1%-12.
3%); P<0.
001 and 15.
0%-12.
4%; P=0.
003）
。

➤ Among them, individuals with high body mass index (BMI), type 2 diabetes, insulin resistance, and severe liver fibrosis may respond better
to ezemab therapy.

➤ There was no significant difference in the degree of hepatic fibrosis (both groups P>0.
05).

➤ CAP (controlled attenuation parameter) for transient elastography was significantly reduced in the combination therapy group (321dB/m-287dB/m; P=0.
018), but no significant change in the monotherapy group (323dB/m-311dB/m; P=0.
104）
。

Summary of this article

The study found the safety and tolerability of ezemab and rosuvastatin in the treatment of NAFLD
.

In addition, ezemab combined with rosuvastatin significantly reduces intrahepatic fat content
.

Introduction of translators

Dong Bingzi

· Doctor of Medicine, Postdoctoral Fellow, Deputy Chief Physician, Department of Endocrinology, Affiliated Hospital of Qingdao University

· Graduated from Tokushima National University (a scholarship student from the Ministry of Education, Culture, Sports, Science and Technology of Japan) and is engaged
in clinical and basic research on bone metabolism.

In recent years, he has published 13 SCI papers as the first/corresponding author, and his research results have been published in JBMR, IntJBiolSci, etc.
, participated in the compilation of 3 monographs, 2 main translations, presided over 1 National Natural Science Foundation of China, 2 provincial and ministerial projects, and participated in 2 provincial and ministerial awards
.

· He is currently a youth member of the Endocrinology Branch of the Chinese Geriatrics Association.
Member of the Osteoporosis and Bone Mineral Salt Disease Branch of Shandong Medical Association

· Member of the Osteoporosis and Bone Mineral Salt Disease Branch of Shandong Medical Doctor Association

· Member and Secretary of Qingdao Medical Association Osteoporosis and Bone Mineral Salt Disease Specialist Branch